Dysplasia Clinical Trial
Official title:
A Phase la Trial of Photodynamic Therapy With HPPH (2-1 (Hexyloxyethyl)-2-devinylpyropheophorbide-a) for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx.
Verified date | October 2018 |
Source | Roswell Park Cancer Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Recent literature suggests that certain patients with squamous cell cancers of the head and neck region may benefit from photodynamic therapy whether or not they may have received prior therapy, e.g. radiation therapy
Status | Completed |
Enrollment | 29 |
Est. completion date | October 1, 2018 |
Est. primary completion date | January 29, 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients with moderate to severe dysplasia and/or squamous carcinoma-in-situ of the oral cavity and/or oropharynx. - Patients with T1 squamous cell carcinoma of the oral cavity and/or oropharynx. - Patient may have primary and/or recurrent lesions to be treated. - Diagnosis must confirmed by biopsy. - Prior therapy of any type is allowed. - Male or female patients at least 18 years old. Female patients must not be pregnant and must be practicing a medically acceptable form of birth control, be sterile or post-menopausal. Male patients should be using a medically acceptable form of birth control or be sterile. - Patients must have an ECOG score of 0-2 (Appendix A 1 ). - Patient or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure. Exclusion Criteria: - Patients with T2 or greater squamous cell carcinoma. - True tongue base lesions (as determined by the treating physician). - Patients with severe trismus that prevents adequate access to the lesion for treatment light delivery (as determined by the treating physician). - Porphyria or hypersensitivity to porphyrin or porphyrin-like compounds. - Patients with impaired hepatic (alkaline phosphatase (hepatic) or SGOT;:3 times the upper normal limits). - Patients with minimal impairment of renal function (total serum bilirubin;: 2 mg/dl, serum creatinine;: 2 mg/dl) - Unwilling or unable to follow protocol requirements. - Any condition which in the Investigator's opinion deems the patient an unsuitable candidate to receive study drug and or light treatment. - Patients on concurrent chemotherapy or radiation therapy or less than 4 weeks after the last dose of chemotherapy or radiation therapy. Inclusion of Women and Minorities: - Both men and women and members of all races and ethnic groups are eligible for this study. |
Country | Name | City | State |
---|---|---|---|
United States | Roswell Park Cancer Institute | Buffalo | New York |
Lead Sponsor | Collaborator |
---|---|
Roswell Park Cancer Institute | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Toxicity | To determine the maximally tolerated dose in the oral cavity and/or oropharynx of photodynamic therapy (PDT) using HPPH (2-1 (hexyloxyethyl)-2- devinylpyropheophorbide-a) and 665 nm light. | 6 weeks | |
Secondary | Tumor response | 3 months | ||
Secondary | Response of dysplasia, CiS and selected patients with T1 squamous cell carcinoma of the oral cavity and/or oropharynx using photodynamic therapy (PDT) with HPPH (2-1 (hexyloxyethyl)-2-devinylpyropheophorbide-a) and 665 nm light. | 3 months | ||
Secondary | Amount of HPPH in the blood prior to light treatment. | 3 months | ||
Secondary | Biomarkers, i.e. STAT3 crosslinks and/or activation status of pro-survival signaling molecules before and after PDT treatment. | 3 months | ||
Secondary | To determine non-invasively HPPH fluorescence and blood flow in To determine non-invasively HPPH fluorescence and blood flow in tumor and surrounding normal tissue before and after PDT | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05809999 -
IBD Neoplasia Surveillance RCT
|
N/A | |
Completed |
NCT04153266 -
Oral Epithelial Dysplasia Informational Needs Questionnaire
|
||
Completed |
NCT05161013 -
A Proof-of-Concept Study Evaluating LINFU™
|
N/A | |
Terminated |
NCT01013831 -
Erlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the Lung
|
Phase 1 | |
Completed |
NCT04072913 -
Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix
|
N/A | |
Completed |
NCT04067778 -
IBD Neoplasia Surveillance Pilot RCT
|
N/A | |
Recruiting |
NCT06281392 -
Artificial Intelligence and Dysplasia Detection in Inflammatory Bowel Disease (EIIDISIA Study)
|
N/A | |
Completed |
NCT05171634 -
Artificial Intelligence and Dysplasia Detection in Ulcerative Colitis (CUDISIA Study)
|
N/A | |
Recruiting |
NCT06430372 -
Study of VEGF-A Targeting NIR-II Fluorescence Endoscopy in the Gastrointestinal Tract
|
Phase 1 | |
Active, not recruiting |
NCT02790853 -
Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders
|
Early Phase 1 | |
Recruiting |
NCT04867590 -
A Study Comparing the Effectiveness of EndoRotor Versus Radiofrequency in Treating Barrett's Esophagus
|
N/A | |
Completed |
NCT02075905 -
Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management
|
N/A | |
Terminated |
NCT02481687 -
The Value of I-Scan and Confocal Laser Endomicroscopy for the Assessment of Chronic Inflammatory Bowel Disease
|
N/A | |
Completed |
NCT01799200 -
Hip Pathomorphology in Collegiate Athletes and Controls
|
N/A | |
Recruiting |
NCT04054713 -
Acetic Acid for the Detection of Esophageal Neoplasms
|
N/A | |
Completed |
NCT03268993 -
Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer
|
N/A | |
Active, not recruiting |
NCT01816438 -
A French Non Interventional Multicentric Cohort Study in Patients With Colorectal Dysplasia
|
||
Terminated |
NCT00358111 -
Study of LUMA Cervical Imaging System as Adjunct to Colposcopy
|
Phase 4 | |
Active, not recruiting |
NCT01688908 -
Efficacy of Endoscopy Screening on Esophageal Cancer in China (ESECC)
|
N/A | |
Completed |
NCT02100189 -
Esophageal Cytology With FISH in Detecting Esophageal Cancer
|
N/A |